Bayer's Stroke Prevention Drug Shows Promise, Reviving Hope for New Blood Clot Treatment Class

Bayer's asundexian succeeds in Phase 3 stroke prevention trial, becoming first FXIa inhibitor to show positive results and potentially opening door for safer blood clot medications.